To date, only one drug has been approved for the treatment of itch (persistent pruritus) and it only targets a small portion of the patient population. Researchers from Mallinckrodt plc have unveiled gastrin-releasing peptide receptor (GRPR) as an itch-specific receptor for nonhistaminergic itch.
Researchers from the University of Arizona presented the discovery of first-in-class dual-specificity tyrosine phosphorylation-regulated kinase 1A/B (DYRK1A/B) proteolysis targeting chimeras (PROTACs) as potential Alzheimer’s disease (AD) therapeutic candidates.
Protein-tyrosine phosphatase SHP-1 is a negative regulator of immune cell function and is broadly expressed in the hematopoietic compartment. Due to its role in immune cell signaling, SHP-1 may be explored as a target for tumor immunotherapy.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Tongji Hospital have disclosed sulfonylurea compounds acting as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of heart failure.
Biotheryx Inc. has entered into a research collaboration and license agreement with Incyte Corp. to discover and develop targeted protein degraders for novel oncology targets.
Montelino Therapeutics LLC has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor variant 7 (AR-v7)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Centre National de la Recherche Scientifique and Université Paul Sabatier - Toulouse III have divulged alkynylcarbinols acting as 17β -hydroxysteroid dehydrogenase 11 (17β-HSD11; 17bHSD11; 17βHSD11)-activated compounds reported to be useful for the treatment of cancer, bacterial, fungal and parasitic infections.
Ubix Therapeutics Inc. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a protein ENL (MLLT1; YEATS1) targeting moiety via linker.
RSS
